ReviewCurrent diabetes reviews2026
Review: Fructose, the Sweet Culprit behind Nonalcoholic Fatty Liver Disease and Type 2 Diabetes.
Review in Current diabetes reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Construction and validation of a diagnostic model for type 2 diabetes mellitus comorbid with metabolic dysfunction-associated steatotic liver disease based on routine serological indicators: a retrospective case-control study.Frontiers in endocrinology · 2026Article
- Fatty liver reexamined choline and mitochondrial toxin amelioration.World journal of biological chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The composition of the diet has altered over the past few decades, with a significant increase in the consumption of dietary sugars, particularly fructose, which has risen more than tenfold. This elevated consumption of fructose and sugars is considered to be one of the major risk aspects for the emergence of obesity and other metabolic disorders. In this review, we discuss the correlation between insulin resistance and NAFLD (nonalcoholic fatty liver disease) due to dietary fructose intake. Type 2 Diabetes Mellitus (T2DM) is spreading quickly over the world and has epidemic proportions. The risk of both hepatic and metabolic abnormalities is increased by their connection, founded on shared metabolic risk factors such as obesity, (IR) Insulin Resistance, and an unhealthy standard of living. This review highlights the prevalence of coexisting T2DM (Type 2 diabetes) and NAFLD (Non-alcoholic Fatty Liver Disease) in the community. In summary, the key pathophysiological pathways and risk stratification algorithms for the onset of nonalcoholic fatty liver disease and type 2 diabetes have been covered.
Indexed as
Identifiers
40176716What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.